IAS 2013: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention June 30 - July 3 2013

Conference Reports for NATAP


IAS 2013: 7th IAS Conference on HIV Pathogenesis Treatment and Prevention June 30 - July 3 2013 Kuala Lumpur, Malaysia

	HIV Prevention at IAS 2013 - Jared Baeten, MD PhD Andrew Mujugira, MBChB MSc MPH Connie Celum, MD MPH University of Washington - (07/10/13) Non-Infectious Complications of HIV and Antiretroviral Therapy - IAS 2013 (Kuala Lumpur, Malaysia) written by Roger Bedimo, MD VA North Texas Health Care System - (07/10/13) Single tablet regimens do not necessarily translate into more durable HIV treatments: "initial use of RAL-based regimens was associated with a better outcome........patients starting HAART with RAL were less likely to change regimen...... the main reason for 1st line discontinuation/switch remain the adverse effects, very few virological failure were observed" - (10/16/13) IAS Towards an HIV Cure Symposium, 29th-30th June 2013, Kuala Lumpur - Written for NATAP by David Margolis MD, UNC Chapel Hill and the Collaboratory of AIDS Researchers for Eradication (CARE) - (08/05/13) Cure Strategies: "Viral and Immune-Targeted Interventions: Hit Me with Your Best Shot" - Oral Session at IAS 2013 Kulala Lumpur June 30-July 3 - (07/30/13) Hepatitis C Re-infection Among HIV+ MSM in London & Prisoners in Spain - (07/24/13) Maraviroc Safety & Efficacy in Children Aged 2-18 - (07/24/13) Update from Study A4001031: maraviroc pharmacokinetics in CCR5-tropic HIV-1-infected children aged 2-<18 years - (07/24/13) Transmitted NNRTI Resistance Rate Climbing in US But Flat in Big European Countries - (07/24/13) Number of regimens rather than cumulative exposure to antiretrovirals associated with lower bone mineral density in HIV-positive subjects - (07/22/13) In Utero HAART Exposure Associated with Decreased Growth among HIV-Exposed Uninfected Breast Fed Infants in Botswana - (07/20/13) Risk of cancer among HIV-positive women in British Columbia, Canada: Importance of screening and detection programs - (07/20/13) Telaprevir Regimen for HIV/HCV Patients With PegIFN/RBV Failure and Cirrhosis - written by Mark Mascolini - (07/20/13) Switching HIV Clinics Linked to Higher Mortality in Large Austrian Study - written by Mark Mascolini - (07/20/13) Number of ART Regimens But Not Time on ART or Tenofovir Tied to Low Bone Density - written by Mark Mascolini - (07/20/13) Maintenance Maraviroc/Raltegravir Controls HIV in Preliminary 10-Person Analysis - written by Mark Mascolini - (07/20/13) ART Linked to Lower Sexual (But Not Drug-Injecting) Risk Behavior in Meta-Analysis - written by Mark Mascolini - (07/20/13) MSM HIV Sex/Substance Abuse Risk Intervention in South Florida: Single 1-on-1 Session Works as Well as 4 Group Sessions in Trimming MSM Risk Behavior - written by Mark Mascolini - (07/20/13) Rates of 2 Non-AIDS Cancers Higher With HIV in British Columbia Women - written by Mark Mascolini - (07/19/13) Less Education Linked to Later HIV Diagnosis, Higher Mortality in 13-Cohort European Study - written by Mark Mascolini - (07/19/13) No Dose Adjustment With Etravirine Plus ATV/r in Treatment Experienced: Randomized Trial - written by Mark Mascolini - (07/19/13) Additional Vaccine-Covered HPV Genotypes Found Yearly in Older HIV+/HIV- Gay Men - written by Mark Mascolini - (07/19/13) Maintenance Maraviroc/Raltegravir Controls HIV in Preliminary 10-Person Analysis - written by Mark Mascolini - (07/19/13) Boosted PI (Kaletra) + NNRTIs Successful as 2nd-Line ART in Africa: EARNEST Study - "A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial" - (07/18/13) Obesity Rate Differs by HIV Status, Gender, Race, and ARV Use in North Carolina - written by Mark Mascolini - (07/18/13) HIV Detectable in Semen of MSM Despite Suppression in Blood: First Longitudinal Study - written by Mark Mascolini - (07/18/13) Bioequivalence of darunavir (800mg) co-administered with cobicistat (150mg) as either a fixed-dose combination tablet or as single agents under fasted and fed conditions in healthy volunteers - (07/18/13) Longitudinal study of bone mineral density and vitamin D levels among perinatally HIV-infected Thai adolescents receiving long-term antiretroviral therapy - (07/18/13) HPV-16 Tied to Development and Clearance of Anal Cancer Precursor in Gay HIV+/HIV- Men - written by Mark - (07/18/13) HIV Detectable in Semen of MSM Despite Suppression in Blood: First Longitudinal Study - written by Mark Mascolini - (07/16/13) Provider-Initiated Testing Turns Up Large Portion of Acute HIV Cases in MSM - (07/15/13) Intimate Partner Violence in Half of US MSM Group Affects Condom-Negotiating Skills - (07/15/13) In HIV-Discordant Gays, Viral Load Perception Strongly Linked to Unprotected Anal Sex - (07/15/13) "Evolutionary Dead-End" After Emergence of Primary Dolutegravir Resistance Mutation? - (07/15/13) HIV infection was associated with an increased risk of hip fracture, independently of age, gender and co-morbidities: a population-based cohort study - (07/15/13) High Transplacental Transfer of Atazanavir But No Hyperbilirubinemia in Neonates - (07/15/13) Efavirenz, Tenofovir, and FTC Levels Higher in Colonic Tissue Than Blood - (07/15/13) The Effect of HIV Infection, ART and Ageing on Renal Function in PLHIV, Chelsea and Westminster Hospital London, UK 1996-2012 - (07/13/13) Etravirine 200mg twice daily combined with atazanavir/ritonavir 300/100mg or 400/100mg once daily in treatment-experienced patients: primary 48-week efficacy and safety analysis of the TEACH trial - (07/13/13) Intelence and prezista Once A Day Study (INROADS): A Multicenter, Single-Arm, Open-Label Study of Once Daily Combination of Etravirine (ETR) and Darunavir/Ritonavir (DRV/r) as Dual Therapy in Early Treatment-Experienced Subjects - (07/13/13) Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years: Week 48 analysis of the ARIEL trial - (07/12/13) ART Started in Primary Infection May "Block Immunologic Storm" in French OPTIPRIM - (07/12/13) Starting ART Above 500 CD4s Cuts HIV DNA in PBMCs, Prompts Bigger CD4 Rebound - written by Mark Mascolini - (07/12/13) Standard Triple Therapy Controls HIV Better Than Raltegravir/Darunavir at 48 Weeks RADAR Study - written by Mark Mascolini - (07/12/13) High Levels of Two Antiretrovirals With Monthly or Quarterly Injections in Healthy Volunteers: GSK744 LAP + TMC278 LA - written by Mark Mascolini - (07/12/13) Long term therapeutic success of etravirine in switch and naive patients - written by Mark Mascolini - (07/12/13) Association between HMG-CoA reductase inhibitors (statins) use and cancer occurrence among HIV-1 treated patients - Statin use reduced incidence of cancers - (07/11/13) Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine (STB) and Cobicistat (COBI) in HIV Infected Patients with Mild to Moderate Renal Impairment - (07/11/13) Early initiation of antiretroviral therapy for individuals with HIV infection: A systematic review - (07/11/13) Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Integrated Week 96 Subgroup Analyses - (07/11/13) EFFECTS ON RENAL FUNCTION OF A SWITCH FROM TENOFOVIR (TDF) TO ABACAVIR (ABC)-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART), WITH OR WITHOUT ATAZANAVIR - (07/11/13) STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Has Non-Inferior Efficacy Compared to Efavirenz/Emtricitabine/Tenofovir DF and Improves Patient Reported Outcomes - (07/11/13) Lower bone mineral density independently associated with both increased bone turnover and HIV-1 infection in HIV-positive subjects compared to HIV-negative subjects - (07/11/13) Stem-cell transplants may purge HIV..... Post-Transplant and Off Drugs, H.I.V. Patients Are Apparently Virus-Free - (07/10/13) Access to HCV triple therapy with telaprevir or boceprevir in real-life setting in HIV-HCV co-infected patients - ANRS CO13 Hepavih Cohort (France) - (07/09/13) Dolutegravir is Non-Inferior to Raltegravir and Shows Durable Response Through 96 Weeks: Results From the SPRING-2 Trial - (07/09/13) Lower Peak Viral Load, Higher CD4/CD8 Ratio Linked to Low PBMC Reservoir - written by Mark Mascolini - (07/09/13) BIT225, a Novel Assembly Inhibitor, Cuts HIV Load in Monocyte Reservoir - written by Mark Mascolini - (07/09/13) Independent Predictors of Carotid Intimal Thickness Differ Between HIV+ and HIV- Patients with Respect to Traditional Cardiac Risk Factors, Risk Calculators, Lipid Subfractions, & Inflammatory Markers (poster) - (07/09/13) Independent Predictors (slides) of Carotid Intimal Thickness Differ Between HIV+ and HIV- Patients with Respect to Traditional Cardiac Risk Factors, Risk Calculators, Lipid Subfractions, and Inflammatory Markers (slide presentation) - (07/09/13) Overall First-Line ART Efficacy Only 60% at 82 Weeks in Meta-Analysis - written by Mark Mascolini - (07/09/13) Life Expectancy With HIV Jumps 15 Years From 2000-2002 to 2006-2007 in US, Canada - written by Mark Mascolini - (07/09/13) Sustained Response to Dolutegravir Through 96 Weeks in Antiretroviral Naive - written by Mark Mascolini - (07/09/13) Different Predictors of ART Switches in IDUs and non-IDUs - written by Mark Mascolini - (07/09/13) Higher Rate of Triple-Class Failure in Pernitally Infected Than Heterosexually Infected - written by Mark Mascolini - (07/09/13) Quick CNS Improvement After Switch From Efavirenz to Raltegravir - written by Mark Mascolini - (07/05/13) Maintenance Therapy With Raltegravir/Etravirine: Virologic Failure Rate 5% at 12 Months - written by Mark Mascolini - (07/05/13) Bid to cure HIV ramps up, New Baby Cure Study/IMPAACT - (07/05/13) First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety, and tolerability in healthy adults - (07/05/13) In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm3 achieves better HIV-1 reservoirs' depletion (HIV-DNA) and T cell count restoration - (07/05/13) Short-Term ART in Primary HIV-Infection & Decrease in HIV-DNA...... "....showed that 12 or 48 weeks of ART significantly decreases the cell-associated HIV-DNA. Also that viral load at 'baseline' associates with HIV-DNA levels at baseline and after therapy" - (07/05/13) HIV[ART] and HCV infections independently contribute to lower bone mineral density but have different effects on bone turnover markers - (07/05/13) Less Bone Loss With Raltegravir Than NRTIs in Second-Line Regimens - written by Mark Mascolini - (07/05/13) Low-Dose (400-mg) Efavirenz vs Standard 600-mg Dose Studied, Found Non-Inferior Low-Dose (400-mg) Efavirenz Not Inferior to Standard 600-mg Dose - written by Mark Mascolini - (07/05/13) Kidney Function Improves With TDF-to-ABC Switch Regardless of Atazanavir Use - written by Mark Mascolini - (07/05/13) Dolutegravir Effective at 24/48 Weeks in People With Integrase Inhibitor Mutations - written by Mark Mascolini - - (07/03/13) Dolutegravir Superior to Raltegravir at 48 Weeks in Integrase Inhibitor Naive - written by Mark Mascolini - - (07/03/13) Renal Safety Similar With Dolutegravir, Raltegravir, and Efavirenz in Antiretroviral Naive - written by Mark Mascolini - - (07/03/13) Two Boston Stem-Cell Transplant Patients Stop Antiretrovirals With No Rebound - written by Mark Mascolini - - (07/03/13) Dolutegravir (DTG) is Superior to Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: Week 48 Results From SAILING (ING111762) - (07/03/13) Once-Daily Dolutegravir (DTG; GSK1349572) Has a Renal Safety Profile Comparable to Raltegravir (RAL) and Efavirenz in Antiretroviral (ART)-Naive Adults: 48 Week Results From SPRING-2 (ING113086) and SINGLE (ING114467) - (07/03/13) WHO issues new ART HIV recommendations calling for earlier treatment - More Conservative Than HHS ART Guidelines - (07/03/13) Aging & Cure - a talk by Steve Deeks, MD at the IAS Conference in Kuala Lumpur - (07/03/13) Phase 3 Assessment of Dolutegravir (DTG) 50 mg Twice Daily (BID) in HIV-1-Infected Subjects With Raltegravir (RAL) and/or Elvitegravir (EVG) Resistance in VIKING-3: Week 24 Results of All 183 Subjects Enrolled - (07/03/13) New HIV 'Cure' Drug To Activate HIV Replication Cyclic Panobinostat (LBH589) dosing in HIV-1 patients: Findings from the CLEAR trial - (07/03/13) SAFETY OF RIBAVIRIN-CONTAINING REGIMENS OF ABT-450/r, ABT-333, AND ABT-267 FOR THE TREATMENT OF HCV GENOTYPE 1 INFECTION AND EFFICACY IN SUBJECTS WITH RIBAVIRIN DOSE REDUCTIONS - (07/03/13) End-Stage Renal Disease Incidence 2 to 4 Times Higher With HIV in North America - written by Mark Mascolini - (07/02/13) Systemic Review Sees Evidence for Advantage to Starting ART Above 500 CD4s - written by Mark Mascolini - (07/02/13) Immune Activation Tied to Viral Blips in People Taking Suppressive ART - (07/02/13) Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals - (07/02/13) Pharmacokinetic (PK) interactions between Boceprevir (BOC) and Atazanavir/r (ATV/r) or Raltegravir (RAL) in HIV/HCV coinfected patients (pts) - (07/02/13) Functional cure after long term HAART initiated during early HIV infection - a case study - (07/02/13) 5-drug HAART during Primary HIV Infection Leads to a Reduction of Proviral DNA Levels in Comparison to Levels Achievable during Chronic Infection - (07/02/13) Effects of renal tubular dysfunction on bone - (07/02/13) Cardiac steatosis (the fatty heart) in cardiovascularly asymptomatic persons with HIV infection - (07/02/13) HIV Detectable in Semen of MSM Despite Suppression in Blood: First Longitudinal Study - written by Mark Mascolini - (07/01/13) Efficacy and Tolerability of Maraviroc for Children With Antiretroviral Experience - written by Mark Mascolini - (07/01/13) Acute Retroviral Syndrome Score Correlates With Signals of Progression - written by Mark Mascolini - (07/01/13) New HIV Life Expectancy study: Women and Aboriginals in British Columbia Fall Far Short of Normal Life Expectancy - written by Mark Mascolini - (07/01/13) Low CD4/CD8 Ratio Predicts Non-AIDS Morbidity, Mortality in ART Responders - written by Mark Mascolini - (07/01/13) Good 48-Week Response to Darunavir in Children With Antiretroviral Experience - written by Mark Mascolini - (07/01/13) Low-Dose Lopinavir/Ritonavir Tablet Noninferior to Full Dose in Thai Children - written by Mark Mascolini - (07/01/13) Long-term virological outcome in HIV-infected children on ART in the UK/Ireland - Higher Failure Rate With Nevirapine Than Efavirenz or PIs in Children in UK and Ireland - written by Mark Mascolini - (07/01/13)